NewAmsterdam Pharma Company NV’s recent filing unveils that its 10% Owner ForGrowth NAP B.V. unloaded Company’s shares for reported $0.76 million on Dec 30 ’24. In the deal valued at $25.54 per share,29,846 shares were sold. As a result of this transaction, ForGrowth NAP B.V. now holds 10,656,172 shares worth roughly $276.42 million.
Then, ForGrowth NAP B.V. sold 41,472 shares, generating $1,076,290 in total proceeds. Upon selling the shares at $25.95, the 10% Owner now owns 10,686,018 shares.
Before that, ForGrowth NAP B.V. sold 33,438 shares. NewAmsterdam Pharma Company NV shares valued at $869,629 were divested by the 10% Owner at a price of $26.01 per share. As a result of the transaction, ForGrowth NAP B.V. now holds 10,727,490 shares, worth roughly $278.27 million.
H.C. Wainwright initiated its NewAmsterdam Pharma Company NV [NAMS] rating to a Buy in a research note published on December 30, 2024; the price target was $48. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Scotiabank began covering NAMS with “Sector outperform” recommendation on March 14, 2024. Guggenheim started covering the stock on January 18, 2024. It rated NAMS as “a Buy”.
Price Performance Review of NAMS
On Friday, NewAmsterdam Pharma Company NV [NASDAQ:NAMS] saw its stock fall -0.08% to $25.94. Over the last five days, the stock has lost -1.11%. NewAmsterdam Pharma Company NV shares have risen nearly 0.93% since the year began. Nevertheless, the stocks have risen 114.91% over the past one year. While a 52-week high of $27.29 was reached on 01/02/25, a 52-week low of $11.57 was recorded on 01/03/25. SMA at 50 days reached $22.37, while 200 days put it at $19.70.
Levels Of Support And Resistance For NAMS Stock
The 24-hour chart illustrates a support level at 25.47, which if violated will result in even more drops to 24.99. On the upside, there is a resistance level at 26.36. A further resistance level may holdings at 26.77. The Relative Strength Index (RSI) on the 14-day chart is 62.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.30%. Stochastics %K at 55.85% indicates the stock is a holding.
How much short interest is there in NewAmsterdam Pharma Company NV?
A steep rise in short interest was recorded in NewAmsterdam Pharma Company NV stocks on 2024-12-13, growing by 1.58 million shares to a total of 2.58 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 1.01 million shares. There was a rise of 60.99%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 16, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $37 price target.
